Patient-physician interpersonal processes of care at the time of diabetes treatment intensification and their links to patient outcomes

2020 ◽  
Author(s):  
Maryam Peimani ◽  
Gholamreza Garmaroudi ◽  
Anita L. Stewart ◽  
MirSaeed Yekaninejad ◽  
Elham Shakibazadeh ◽  
...  
Keyword(s):  
Patient Outcomes ◽  
Diabetes Treatment ◽  
Interpersonal Processes ◽  
Treatment Intensification ◽  
Processes Of Care

Interpersonal Processes of Care Survey

2007 ◽  
Author(s):  
Anita L. Stewart ◽  
Anna M. Nápoles-Springer ◽  
Steven E. Gregorich ◽  
Jasmine Santoyo-Olsson
Keyword(s):  
Interpersonal Processes ◽  
Processes Of Care ◽  
Care Survey

Interpersonal Processes of Care Scales

1999 ◽  
Author(s):  
Anita L. Stewart ◽  
Anna Nápoles-Springer ◽  
Eliseo J. Prez-Stable ◽  
Samuel F. Posner ◽  
Andrew B. Bindman ◽  
...  
Keyword(s):  
Interpersonal Processes ◽  
Processes Of Care

scholarly journals 4070 Association of Interpersonal Processes of Care and Health Outcomes in Patients with Type II Diabetes

2020 ◽  
Vol 4 (s1) ◽  
pp. 80-81
Author(s):  
Hadley Reid ◽  
Olivia M Lin ◽  
Rebecca L Fabbro ◽  
Kimberly S Johnson ◽  
Laura P. Svetkey ◽  
...  
Keyword(s):  
Medication Adherence ◽  
Type Ii Diabetes ◽  
Primary Outcome ◽  
Patient Perceptions ◽  
Secondary Outcome ◽  
Diabetic Patients ◽  
Type Ii ◽  
Interpersonal Processes ◽  
Processes Of Care ◽  
Perceptions Of Care

OBJECTIVES/GOALS: 1. Understand the association between patient perceptions of care measured by the Interpersonal Processes of Care (IPC) Survey and glycemic control, appointment no-shows/cancellations and medication adherence in patients with type II diabetes. 2. Determine how these relationships differ by race for non-Hispanic White and Black patients. METHODS/STUDY POPULATION: This is a cross-sectional study of a random sample of 100 White and 100 Black Type II diabetic patients followed in Duke primary care clinics and prescribed antihyperglycemic medication. We will recruit through email and phone calls. Enrolled patients will complete the Interpersonal Processes of Care Short Form and Extent of Medication Adherence survey to measure patient perceptions of care (predictor) and medication adherence (secondary outcome). No show appointments and cancellations (secondary outcomes) and most recent hemoglobin A1c (primary outcome) will be collected from the Electronic Medical Record. We will also collect basic demographic information, insurance status, financial security, significant co-morbidities, and number and type (subcutaneous vs oral) of antihyperglycemic medications. RESULTS/ANTICIPATED RESULTS: -The study is powered to detect a 0.6% difference in HbA1c, our primary outcome, between high and low scorers on the Interpersonal Processes of Care subdomains. -We expect that higher patient scores in the positive domains of the IPC survey and lower DISCUSSION/SIGNIFICANCE OF IMPACT: This study will provide information to develop and implement targeted interventions to reduce racial and ethnic disparities in patients with Type II diabetes. We hope to gain information on potentially modifiable factors in patient-provider interactions that can be intervened upon to improve prevention and long-term outcomes in these populations.

scholarly journals Development of the Interpersonal Processes of Care Survey–Japanese version

2020 ◽  
Vol 40 (1) ◽  
pp. 107-112
Author(s):  
Takuma Shiozawa ◽  
Sosei Yamaguchi ◽  
Asami Matsunaga ◽  
Utako Sawada ◽  
Chiyo Fujii
Keyword(s):  
Japanese Version ◽  
Interpersonal Processes ◽  
Processes Of Care ◽  
Care Survey

Relationships of Processes of Care to Patient Outcomes

1979 ◽  
Vol 28 (2) ◽  
pp. 85???93 ◽  
Author(s):  
Barbara Given ◽  
C. William Given ◽  
Lewis E. Simoni
Keyword(s):  
Patient Outcomes ◽  
Processes Of Care

scholarly journals Interpersonal Processes of Care in Diverse Populations

1999 ◽  
Vol 77 (3) ◽  
pp. 305-339 ◽  
Author(s):  
Anita L. Stewart ◽  
Anna Nápoles‐Springer ◽  
Eliseo J. Pérez‐Stable
Keyword(s):  
Diverse Populations ◽  
Interpersonal Processes ◽  
Processes Of Care

scholarly journals Ertugliflozin: a novel anti-diabetic drug

2018 ◽  
Vol 7 (12) ◽  
pp. 2472
Author(s):  
Vikrant Sharma ◽  
Sonika Sharma ◽  
Sanjay Jaiswal ◽  
Ravi R. Ghanghas ◽  
Durgaprasad Bodepalli ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Patient Outcomes ◽  
Sglt2 Inhibitors ◽  
Treatment Modalities ◽  
Diabetes Treatment ◽  
Sodium Glucose Cotransporter ◽  
Tract Infections ◽  
Convoluted Tubules ◽  
Mycotic Infections

Diabetes Mellitus is a disorder of global proportion. Despite various treatment modalities presently being available, yet the desired glycaemic control and patient outcomes have not been achieved completely. Sodium glucose co-transporter type 2 inhibitors (SGLT2 inhibitors) are one such promising group of emerging drugs in diabetes treatment. Ertugliflozin prevents the reabsorption of glucose by inhibiting sodium-glucose cotransporter-2 (SGLT2) at proximal convoluted tubules. Ertugliflozin is available as 5mg and 15mg tablets. Ertugliflozin has been related to genital mycotic infections and urinary tract infections. Benefits of Ertugliflozin include better control on blood glucose, body weight and blood pressure.

Sign in / Sign up

Export Citation Format

Share Document